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A B S T R A C T
Background
Acquired brain injury can cause eye movement disorders which may include: strabismus, gaze deficits and nystagmus, causing visual
symptoms of double, blurred or ’juddery’ vision and reading difficulties. A wide range of interventions exist that have potential to
alleviate or ameliorate these symptoms. There is a need to evaluate the effectiveness of these interventions and the timing of their
implementation.
Objectives
We aimed to assess the effectiveness of any intervention and determine the effect of timing of intervention in the treatment of strabismus,
gaze deficits and nystagmus due to acquired brain injury. We considered restitutive, substitutive, compensatory or pharmacological
interventions separately and compared them to control, placebo, alternative treatment or no treatment for improving ocular alignment
or motility (or both).
Search methods
We searched the Cochrane Central Register of ControlledTrials (CENTRAL) (containing the Cochrane Eyes and Vision Trials Register)
(2017, Issue 5), MEDLINE Ovid, Embase Ovid, CINAHL EBSCO, AMEDOvid, PsycINFOOvid, Dissertations & Theses (PQDT)
database, PsycBITE (Psychological Database for Brain Impairment Treatment Efficacy), ISRCTN registry, ClinicalTrials.gov, Health
Services Research Projects in Progress (HSRProj), National Eye Institute Clinical Studies Database and theWorld Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP). The databases were last searched on 26 June 2017. No date or
language restrictions were used in the electronic searches for trials. We manually searched the Australian Orthoptic Journal, British and
Irish Orthoptic Journal, and ESA, ISA and IOA conference proceedings. We contacted researchers active in this field for information
about further published or unpublished studies.
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Selection criteria
We included randomised controlled trials (RCTs) of any intervention for ocular alignment or motility deficits (or both) due to acquired
brain injury.
Data collection and analysis
Two review authors independently selected studies and extracted data. We used standard methods expected by Cochrane. We employed
the GRADE approach to interpret findings and assess the quality of the evidence.
Main results
We found five RCTs (116 participants) that were eligible for inclusion. These trials included conditions of acquired nystagmus, sixth
cranial nerve palsy and traumatic brain injury-induced ocular motility defects. We did not identify any relevant studies of restitutive
interventions.
We identified one UK-based trial of a substitutive intervention, in which botulinum toxin was compared with observation in 47 people
with acute sixth nerve palsy. At four months after entry into the trial, people given botulinum toxin were more likely to make a full
recovery (reduction in angle of deviation within 10 prism dioptres), compared with observation (risk ratio 1.19, 95% CI 0.96 to
1.48; low-certainty evidence). These same participants also achieved binocular single vision. In the injection group only, there were
2 cases of transient ptosis out of 22 participants (9%), and 4 participants out of 22 (18%) with transient vertical deviation; a total
complication rate of 24% per injection and 27% per participant. All adverse events recovered. We judged the certainty of evidence
as low, downgrading for risk of bias and imprecision. It was not possible to mask investigators or participants to allocation, and the
follow-up between groups varied.
We identified one USA-based cross-over trial of a compensatory intervention. Oculomotor rehabilitation was compared with sham
training in 12 people with mild traumatic brain injury, at least one year after the injury. We judged the evidence from this study to
be very low-certainty. The study was small, data for the sham training group were not fully reported, and it was unclear if a cross-over
study design was appropriate as this is an intervention with potential to have a permanent effect.
We identified three cross-over studies of pharmacological interventions for acquired nystagmus, which took place in Germany and the
USA. These studies investigated two classes of pharmacological interventions: GABAergic drugs (gabapentin, baclofen) and aminopy-
ridines (4-aminopyridines (AP), 3,4-diaminopyridine (DAP)). We judged the evidence from all three studies as very low-certainty
because of small numbers of participants (which led to imprecision) and risk of bias (they were cross-over studies which did not report
data in a way that permitted estimation of effect size).
One study compared gabapentin (up to 900 mg/day) with baclofen (up to 30 mg/day) in 21 people with pendular and jerk nystagmus.
The follow-up period was two weeks. This study provides very low-certainty evidence that gabapentin may work better than baclofen
in improving ocular motility and reducing participant-reported symptoms (oscillopsia). These effects may be different in pendular and
jerk nystagmus, but without formal subgroup analysis it is unclear if the difference between the two types of nystagmus was chance
finding. Quality of life was not reported. Ten participants with pendular nystagmus chose to continue treatment with gabapentin, and
one with baclofen. Two participants with jerk nystagmus chose to continue treatment with gabapentin, and one with baclofen. Drug
intolerance was reported in one person receiving gabapentin and in four participants receiving baclofen. Increased ataxia was reported
in three participants receiving gabapentin and two participants receiving baclofen.
One study compared a single dose of 3,4-DAP (20 mg) with placebo in 17 people with downbeat nystagmus. Assessments were made
30 minutes after taking the drug. This study provides very low-certainty evidence that 3,4-DAP may reduce the mean peak slow-phase
velocity, with less oscillopsia, in people with downbeat nystagmus. Three participants reported transient side effects of minor perioral/
distal paraesthesia.
One study compared a single dose of 4-AP with a single dose of 3,4-DAP (both 10 mg doses) in eight people with downbeat nystagmus.
Assessments were made 45 and 90 minutes after drug administration. This study provides very low-certainty evidence that both 3,4-
DAP and 4-AP may reduce the mean slow-phase velocity in people with downbeat nystagmus. This effect may be stronger with 4-AP.
Authors’ conclusions
The included studies provide insufficient evidence to inform decisions about treatments specifically for eye movement disorders that
occur following acquired brain injury. No information was obtained on the cost of treatment or measures of participant satisfaction
relating to treatment options and effectiveness. It was possible to describe the outcome of treatment in each trial and ascertain the
occurrence of adverse events.
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P L A I N L A N G U A G E S U M M A R Y
Interventions for eye movement disorders due to acquired brain injury
What is the aim of this review?
The aim of this Cochrane Review was to find out what treatments work well to improve eye position and eye movement disorders due
to acquired brain injury, and when is the best time to use them.
Key messages
The evidence on the benefits and harms of treatments for eye movement disorders due to acquired brain injury is currently very low-
certainty.
What was studied in this review?
Acquired brain injury is any injury that occurs after birth and causes damage to the brain’s function. Strabismus is a condition in
which the eyes are out of alignment, with one or both eyes turned in, out, up or down. Ocular motility (eye movement) disorders are
defects that prevent normal movement of the eyes. Nystagmus is a condition where the eye movements are not steady and, instead, the
eyes wobble. Treatment options include eye therapy, glasses, prisms, occlusion, botulinum toxin or surgery, to reduce the deviation or
movement of the eyes. Currently there are no clear recommendations on when is best to provide these treatments, how much these
treatments cost and whether treatments are of benefit to people with eye alignment and movement disorders occurring after acquired
brain injury.
What are the main results of this review?
Cochrane researchers found five relevant studies with a total of 116 participants. One study was from the UK and looked at botulinum
toxin compared to observation in people with recent onset sixth nerve palsy. One study from the USA compared eyemovement training
with sham (false) training in people with mild traumatic brain injury. Three studies took place in Germany or the USA and compared
medical drug treatments in people with acquired nystagmus. The review provides:
low-certainty evidence that people with sixth nerve palsy may have a slightly better chance of a reduction in visual symptoms when
given botulinum toxin compared with no treatment.
very low-certainty evidence on eye movement treatment for people with brain injury due to trauma and use of medical drugs for
nystagmus, where treatments show slightly better improved symptoms.
How up-to-date is this review?
Cochrane researchers searched for studies that had been published up to 26 June 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Botulinum toxin versus observat ion in people with sixth nerve palsy
Participant or population: people with sixth nerve palsy
Setting: hospital
Intervention: botulinum toxin
Comparison: observat ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with observation Risk with botulinum
toxin
Improvement in ocular
motility (ocular align-
ment ≤ 10 prism diop-
tres)
Follow-up to 4 months
800 per 1,000 952 per 1,000
(768 to 1,000)
RR 1.19
(0.96 to 1.48)
47
(1 RCT)
⊕⊕©©
LOW 1
Achievement of binocu-
lar single vision (fusion
and stereopsis present)
Follow-up to 4 months
800 per 1,000 952 per 1,000
(768 to 1,000)
RR 1.19
(0.96 to 1.48)
47
(1 RCT)
⊕⊕©©
LOW 1
Improvement in func-
t ional ability
- - - - - Not reported
Quality of lif e - - - - - Not reported
Adverse events.
Follow-up to 4 months
In the inject ion group only, there were 2/ 22 (9%) cases of transient ptosis
and 4/ 22 (18%) with transient vert ical deviat ion, with a total complicat ion
rate of 24% per inject ion and 27% per part icipant. All adverse events
recovered within the follow-up t ime period of 6 months with no last ing
adverse ef fects
47
(1 RCT)
⊕⊕©©
LOW 1
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level for risk of bias (invest igators were aware of the randomisat ion and it was not possible to mask
invest igators or part icipants to the allocat ion and there was variable follow-up between groups) and downgraded one level
for imprecision (conf idence intervals include 1, no ef fect).
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B A C K G R O U N D
Description of the condition
Acquired brain injury is brain damage caused by events occurring
after birth that result in permanent or temporary changes in cog-
nition, physical, emotional and behavioural function. Thismay be
due to trauma, surgery, stroke, brain tumour, infection, inflamma-
tion and ischaemia. Eye movement disorders following acquired
brain injury may include strabismus, gaze deficits and nystagmus
(Rowe 2003). In acquired brain injury, these eye movement dis-
orders are caused by damage to the cranial nerves that supply the
extra ocular muscles or to damage of the neurological areas that
contribute to the control of eye movements (Pierrot-Deseilligny
2011). The incidence of visual problems in acquired brain injury
is unknown but estimates are available for certain types of acquired
brain injury. For example, over half of stroke survivors have visual
impairments (Freeman 1988), and up to 68% of stroke survivors
with visual symptoms have eyemovement disorders (Rowe 2009).
These impact on daily life by causing a range of difficulties includ-
ing inability to maintain normal ocular alignment or move the
eyes appropriately (Hepworth 2016; Jones 2006; Pedersen 1981;
Rowe 2011a). Functional disabilities occur including loss of depth
perception, reduced hand-eye co-ordination and reading impair-
ment (Hepworth 2016;MacIntosh 2003; Rowe 2011b), and these
may impede the effectiveness of rehabilitation therapy in regain-
ing mobility, activities of daily living and quality of life (Ciuffreda
2007; MacIntosh 2003).
The true incidence of eyemovement disorders in acquired brain in-
jury is unknown and the prevalence varies depending on the cause
of brain injury and area of brain involved. Strabismus is a deviation
of the ocular alignment where one eye turns and which may be
intermittent or constant (Fowler 1996; Rowe 2010). Strabismus
occurs in a number of forms including: esotropia (in-turning de-
viation), exotropia (out-turning deviation) or less commonly, hy-
pertropia (up-turning deviation), hypotropia (down-turning de-
viation) and cyclotropia (rotatory deviation). Gaze deficits include
disorders of the eyemovement systemswhich involve saccades (fast
movements of the eyes), smooth pursuits (slow, tracking move-
ments of the eyes), vergence (opposite movements of the eyes such
as convergence where both eyes turn inwards symmetrically or
divergence where both eyes turn outwards), cranial nerve palsy
(impairment of III, IV or VI nerve function causing abnormal
eye movement and strabismus in the affected eye), bilateral gaze
palsy (impaired horizontal, vertical or combined movements in
both eyes), unilateral gaze palsy (internuclear ophthalmoplegia,
one and a half syndrome) and vestibulo-ocular and opto-kinetic
reflexes (involuntary movements of the eyes in response to mov-
ing objects and movement of the head and body) (Pedersen 1981;
Rowe 2011a; Rowe 2013a). Nystagmus is a condition in which
there are frequent involuntary oscillations of the eyes that result
in reduced visual function (Rowe 2008).
Symptoms of eye movement disorders can include blurring of vi-
sion, diplopia (double vision), impaired depth (3-dimensional)
perception, wobbling and jumbling of images, and reading diffi-
culty (Rowe 2013b).
Description of the intervention
There are various treatments associatedwith strabismus, eyemove-
ment disorders and nystagmus. Primarily, treatment is directed at
aligning the visual axes and improving the movement of the eyes.
Treatments for eye movement disorders can be described as resti-
tution, compensation, substitution or pharmacology (Kerkhoff
2000; Pollock 2011). Restitutive treatment aims to restore visual
function to normal; compensatory treatments aims to aid adap-
tation to the persistent visual impairment and substitutive treat-
ments aim to use optical or medical aids to enhance visual func-
tion. Pharmacological treatments aim to reduce the effects of visual
impairment. Restitutive interventions may include convergence
training, pursuit training and saccade training. Compensative in-
terventionsmay include training eyemovements for reading, com-
pensatory head posture or movements, use of eye blinks or colour
cues and training in activities of daily living (Rowe 2011a). Sub-
stitutive interventions may include prisms, eye patches, lens alter-
ation, extra ocular muscle surgery, botulinum toxin, magnification
and environmental modification (Pigassou 1972). Pharmacologi-
cal interventions may include prescription drugs such as baclofen,
memantine and carbamazepine, and local anaesthetic injections
(Choudhuri 2007; Thurtell 2010).
Commencement of interventions can be at multiple time points.
People are offered interventions at different time points dependent
on the time lapse since acquired brain injury onset, severity and
type of symptoms and extent of recovery, if any. Some interven-
tions can be used at any time point such as prisms, occlusion and
lenses, whereas others - such as surgery - tend to be offered later
once a visual condition is stable.
How the intervention might work
Restitution
Restitution includes the biochemical events that help restore func-
tional neural tissue through the reductionof oedema, absorptionof
blood, restoration of normal neuronal physiology, and restoration
of axon transport (Pollock 2011). Treatments of positive fusional
amplitudes and stereopsis through repetition training of specific
deficient functions, such as convergence insufficiency, have been
reported as effective (Kerkhoff 2000). Restitutive interventions
will include those where there is direct training of the impaired
function or repetitive stimulation of eye movement.
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Compensation
Compensation aims to improve the mismatch between the par-
ticipants’ skills and the demands placed on them by their envi-
ronment, by teaching participants to compensate or adapt using
a spared or intact function (Kerkhoff 1999; Kerkhoff 2000).
Substitution
Substitution involves adaptation of visual components that have
been lost or disrupted through the use of optic devices, extra-ocular
muscle surgery, botulinum toxin or environmental modifications
(Kerkhoff 1999; Kerkhoff 2000).
Pharmacology
Pharmacology aims to improve visual functioning through al-
teration of biochemical and/or physiological effects in the body.
Gabapentin is proposed to interact with a high affinity binding site
in brainmembranes linked to calcium channels. It increasesGABA
synthesis. Baclofen is a derivative of GABA. It is proposed to ac-
tivate GABA receptors and acts as an inhibitory neurotransmitter
by blocking monosynaptic and polysynaptic reflexes. Aminopy-
ridines are proposed to bind to open and non-conducting aspects
of potassium ion channels resulting in prolonged action potentials
and allowing increased neurotransmitter release at the neuromus-
cular junction.
Why it is important to do this review
There aremany forms of interventions for eyemovement disorders
that occur following acquired brain injury. Although the natural
history of acquired brain injury differs dependent on the cause,
the treatment of the resultant eyemovement disorder is principally
the same regardless of cause. Although the cause may recover or
progress, the resultant eye movement disorder may persist and
requires treatment to alleviate or reduce visual symptoms.We have
considered all interventions for all types of eyemovement disorders
regardless of cause and evolution of eye movement disorder. We
extracted data for improving, stable or deteriorating eyemovement
disorders.
There are multiple time points at which interventions for eye
movement disorders that occur following acquired brain injury
may be provided. The timing of provision of treatment for eye
movement disorders differs for the various treatment options. In
the early stages, treatment may include conservative options such
as eye patching or prisms which are used whilst the eye movement
disorder is monitored until it improves or stabilises. Where eye
movement disorders persist, further treatment options such as bo-
tulinum toxin or extra ocular muscle surgery may then be consid-
ered. There can be delays in referral of participants with acquired
brain injury to eye care services and thus participants may not re-
ceive treatment early even though treatment options are available.
This delay may impede general rehabilitation.
A recent systematic review of interventions for eye movement dis-
orders in stroke found insufficient evidence to reach conclusions
about the effectiveness of those interventions for this group of
participants (Pollock 2011). There was an absence of relevant ev-
idence and the authors gave an urgent recommendation for high-
quality research. Furthermore, there is no consensus for what con-
stitutes the optimum timing for commencing interventions for eye
movement disorders due to stroke. Timing may vary dependent
on the type of treatment being considered (e.g. eye patch versus
extra-ocular muscle surgery) and/or the extent of visual symptoms
(minimal versus severe impact on daily life). Because this review
only concentrated on stroke populations, one recommendation
was for a systematic review of interventions for eye movement
disorders in participants with acquired brain injury in order to
synthesise the current evidence base, to guide current practice and
aid in the development of well-designed randomised controlled
trials (RCTs). Other publications reporting efficacy and timing
of interventions for eye movement disorders include populations
with varied causes of brain damage such as tumours, inflamma-
tion, infection, stroke and metabolic causes.
Purpose
We have undertaken a high-quality systematic review of the exist-
ing evidence base in order to determine the evidence for effective-
ness and timing of any treatment or management approaches for
all adult participants with acquired brain injury with eye move-
ment disorders. This review directly addressed the recommenda-
tions of the Cochrane systematic review on interventions for eye
movement disorders in stroke (Pollock 2011), i.e. conduct a sys-
tematic review of interventions for eyemovement disorders in par-
ticipants with acquired brain injury in order to synthesise the cur-
rent evidence base. This review examined the timing of interven-
tions for eye movement disorders. The impact on objective and
subjective measures of ocular alignment and motility are reported.
This review can be used to guide current practice and aid in the
development of well-designedRCTs which follow theUKMedical
ResearchCouncil guidance on developing and evaluating complex
interventions (Craig 2008).
O B J E C T I V E S
We aimed to assess the effectiveness of any intervention and deter-
mine the effect of timing of intervention in the treatment of stra-
bismus, gaze deficits and nystagmus due to acquired brain injury.
We considered restitutive, substitutive, compensatory or pharma-
cological interventions separately and compared them to control,
placebo, alternative treatment or no treatment for improving oc-
ular alignment or motility (or both).
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) andquasi-RCTs.
We included cross-over trials if sufficient time was justified for the
wash-out period between interventions to avoid carry-over effects,
or where the condition was stable prior to recruitment, and where
long-term follow-up was not required.
Types of participants
We included individuals with eye movement disorders due to ac-
quired brain injury. We included trials of mixed aetiologies where
more than 50% of participants had acquired brain injury. We ex-
cluded participants with primary diagnoses of multiple sclerosis
(an immune-modulated process affecting the central nervous sys-
tem, causing damage to the myelin sheath of nerve fibres) and
degenerative conditions of the brain (such as Parkinson’s disease,
Huntingdon’s disease and Alzheimer’s). The type of eyemovement
disorder could include III, IV, and VI cranial nerve palsy, reduced
fixation, gaze holding, horizontal or vertical gaze palsy (or both),
internuclear ophthalmoplegia, one and a half syndrome, saccadic
problems, smooth pursuit problems, strabismus, nystagmus, re-
duced convergence or divergence, conjugate deviation and skew
deviation. The deviation of eye movement could be horizontal,
vertical or torsional and the severity of eye movement disorder
could be slight, small, moderate or marked, and could include
paralysis or paresis. We included monocular and binocular eye
movement disorders.
We accepted studies that included participants based on symp-
toms which can be assumed to be present as a direct result of an
eye movement disorder. Symptoms could include double vision,
blurred vision, reading difficulty, wobbling or jumbled vision and
excessive head movements. We considered participants of all ages
from studies of adults and children.
Types of interventions
We included any intervention that aimed to improve the defects
of eye movement, or alleviate or reduce the visual symptoms asso-
ciated with the disorder. We classified interventions as restitution,
substitution, compensation or pharmacological. We included tri-
als that documented the timing (recorded as time period from the
onset of eye movement disorder) of any intervention that aimed
to improve the defects of eye movement, or alleviate or reduce the
visual symptoms associated with the disorder.We classified timing
as early or late intervention, where early constituted intervention
within one month of eye movement disorder onset.
Types of outcome measures
Where possible, we assessed each outcome as a dichotomous vari-
able (yes or no) at the end of the intervention period and at a fol-
low-up point (ideally a minimum of three months after the com-
pletion of the intervention and a maximum of 12 months after).
Primary outcomes
• Improvement in ocular motility measured by orthoptic
assessments of reduction in the angle of deviation (within 10
prism dioptres of ortho/straight position) and/or extent of eye
movement range (improvement of one or more grades of
limitation ranging from 1 to 4), such that visual axes are aligned
in primary or secondary gaze positions (or both)
Secondary outcomes
• Achievement of binocular single vision as assessed by cover
test, motor fusional vergences and stereoacuity
• Reduction of, or alleviation of, participant-reported
symptoms assessed by participant record notes or questionnaire
• Improvement in functional ability measured by validated
measures such as activity of daily living questionnaires
• Quality of life data - any measure of participant or parent
satisfaction relating to improvement in appearance or
improvement to lifestyle
Adverse events
• Intractable permanent diplopia, perforating injury,
symptomatic over- or under-correction, death
• Assessed by descriptive documentation
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist conducted
systematic searches in the following databases for randomised con-
trolled trials and controlled clinical trials. There were no language
or publication year restrictions. The date of the search was 26 June
2017.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 5) (which contains the Cochrane Eyes
and Vision Trials Register) in the Cochrane Library (searched 26
June 2017) (Appendix 1);
• MEDLINE Ovid (1946 to 26 June 2017) (Appendix 2);
• Embase Ovid (1980 to 26 June 2017) (Appendix 3);
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature) (1982 to 26 June 2017) (Appendix 4);
• AMED (Allied and Complementary Medicine Database)
(1985 to 26 June 2017) (Appendix 5);
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• PsycINFO (1967 to 26 June 2017) (Appendix 6);
• Dissertations & Theses (PQDT) database ( http://
pqdtopen.proquest.com/search.html; searched 26 June 2017)
(Appendix 7);
• PsycBITE ( Psychological Database for Brain Impairment
Treatment Efficacy) ( http://www.psycbite.com/search.php:
searched 26 June 2017) (Appendix 8);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch;
searched 26 June 2017) (Appendix 9);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( www.clinicaltrials.gov; searched 26 June
2017) (Appendix 10);
• Health Services Research Projects in Progress ( HSRProj) (
wwwcf.nlm.nih.gov/hsr project/home proj.cfm; searched 26
June 2017) (Appendix 11);
• National Eye Institute Clinical Studies Database (
clinicalstudies.info.nih.gov/cgi/protinstitute.cgi?NEI.0.html;
searched 26 June 2017) (Appendix 12);
• World Health Organization International Clinical Trials
Registry Platform ( www.who.int/ictrp; searched 26 June 2017)
(Appendix 13).
Searching other resources
We searched the reference lists of included trials to identify any
further studies and checked the references of review articles about
vision after acquired brain injury. We performed citation tracking
usingWeb of Science Cited Reference Search for all included stud-
ies and contacted experts in the field, including authors of included
trials and excluded studies identified as possible preliminary or pi-
lot work. We searched reference material supplied by commercial
companies who provide interventions aimed at restoration of eye
movements.
We handsearched the following resources from their inception
to the current date at http://pcwww.liv.ac.uk/ rowef/index files/
Page646.htm.
• British and Irish Orthoptic Journal
• Australian Orthoptic Journal
• Proceedings of the European Strabismological Association
(ESA)
• International Strabismological Association (ISA)
• International Orthoptic Association (IOA)
Data collection and analysis
We followed guidance in Chapter 7 of the Cochrane Handbook for
Systematic Reviews of Interventions for data collection and Chap-
ter 9 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions for data analysis (Deeks 2011; Higgins 2011a). We also
conformed to the Preferred Reporting Items for Systematic Re-
views andMeta-Analyses (PRISMA) checklist (Moher 2009). The
Cochrane Eyes and Vision group Information Specialist ran all
the electronic searches, downloaded references into bibliographic
software, and removed duplicates. Two review authors excluded
any titles or abstracts which were obviously not related to acquired
brain injury and vision. They independently considered each of
these titles and abstracts and excluded any studies where the inter-
vention was not specifically aimed at improving the eyemovement
disorder or the participant’s ability to cope with the eyemovement
disorder. We resolved any disagreements through discussion. We
obtained the full papers for any studies included at this stage.
Selection of studies
Two review authors independently applied the selection criteria,
considering and documenting the type of studies, type of partic-
ipants, intervention, comparison intervention, and the outcome
measures. Each review author classified each study as ’include’
or ’exclude’. For disagreement between these two review authors,
consensus was planned through discussion involving a third re-
view author. In practice, this was not required.
We listed all excluded studies (that we had obtained a full-text
copy for) that included participants with eye movement disorders
in the Characteristics of excluded studies table with the reasons for
exclusion.We did not list studies in the Characteristics of excluded
studies table that were excluded because they included participants
that did not have eye movement disorders (i.e. visual neglect, age-
related visual problems, or visual field loss), unless the two review
authors agreed that there was a clear reason to do so.
Data extraction and management
We used a pre-designed data extraction form to record data from
the included studies. Two review authors independently docu-
mented information found in the table in Appendix 14. If there
were any discrepancies between data extracted by the two review
authors, they were resolved through discussion. Data were entered
into Review Manager 5 (Review Manager 2014).
Assessment of risk of bias in included studies
We used Cochrane’s tool for assessing risk of bias for randomised
trials as outlined in Chapter 8 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011b). We assessed se-
quence generation, allocation concealment, masking (blinding) of
participants, personnel and outcome assessors, incomplete out-
come data and selective outcome reporting. We judged each do-
main as “low risk of bias”, “high risk of bias” or “unclear”. We
also considered additional potential sources of bias for cross-over
studies (Higgins 2011c), namely: (1) whether the cross-over de-
sign is suitable; (2) whether there is a carry-over effect; (3) whether
only first period data are available; (4) incorrect analysis; and (5)
comparability of results with those from parallel-group trials.
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Measures of treatment effect
There was only one study that reported outcomes in a way that
could be analysed in this review. This parallel group study reported
dichotomous outcomes (reduction in angle of deviation within
10 prism dioptres, achievement of binocular single vision). We
analysed these as risk ratios with 95% confidence intervals.
Most (four out of five) studies were cross-over trials. Ideally we
would have extracted the results of paired analyses, but these were
not available.
SeeDifferences between protocol and review for further discussion
of our planned methods.
Unit of analysis issues
The interventions are normally applied at individual level. Some
interventions (e.g. prisms for diplopia or field defect, monocular
occlusion) are used to treat only one eye. In these instances, there
is no unit of analysis issue as the unit of randomisation is the same
as the unit of analysis. However, some interventions (e.g. scan-
ning eye exercises, extra-ocular muscle surgery, pharmacological
interventions) treat both eyes. We report outcome measures for
the person.
We followed guidance in the Cochrane Handbook for Systematic
Reviews of Interventions for the incorporation of data from cross-
over trials, i.e. estimating mean and standard errors from paired
analysis (Higgins 2011c).
Dealing with missing data
If an included study did not report a particular outcome, we did
not include that study in the analyses of that outcome. If an in-
cluded study had missing data (e.g. participants lost to follow-up)
we reported results for included participants based on the raw data
provided. We used all trial data even if intention-to-treat analy-
sis was not conducted. However, we looked at which participants
dropped out or changed treatment to determine if these related
to one specific group or were dispersed across all groups. We also
contacted trial authors for missing data.
Assessment of heterogeneity
We assessed for heterogeneity primarily by examining the charac-
teristics of the study. We did not conduct a meta-analysis due to
clinical heterogeneity, so we did not implement our other planned
methods for assessing heterogeneity. See Differences between
protocol and review.
Assessment of reporting biases
We assessed the possibility of selective outcome reporting as de-
tailed in the Assessment of risk of bias in included studies sec-
tion. We did not conduct any meta-analyses so we did not use our
planned methods for assessing publication bias. See Differences
between protocol and review.
Data synthesis
We provide a narrative account of the data available. See
Differences between protocol and review for details of planned
methods for data synthesis that were not used.
Subgroup and sensitivity analyses
Due to the small number of studies identified, we were unable
to conduct our planned subgroup and sensitivity analyses. See
Differences between protocol and review.
’Summary of findings’ table
Weaimed toprepare a ’Summary of findings’ table for each relevant
comparison including all pre-specified outcomes:
• improvement in ocular motility;
• achievement of binocular single vision;
• improvement in functional ability;
• quality of life;
• adverse effects.
The cross-over studies were not reported in a way that permit-
ted calculation of effect sizes so we have reported the direction,
rather than the size of the effect in these cases. We graded the
certainty of the evidence using the GRADE approach (Guyatt
2008; GRADEpro 2014). In the absence of pooled data we were
guided by the implementation of GRADE for a narrative sum-
mary (Murad 2017).We consideredmethodological limitations of
the included studies, indirectness, imprecision, inconsistency and
likelihood of publication bias. We did not pre-specify the ’Sum-
mary of findings’ table and GRADE assessment in the protocol.
See Differences between protocol and review.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 5049 references (Figure
1). The Cochrane Information Specialist removed 330 duplicate
records and we screened the remaining 4719 reports. We rejected
4700 records after reading the abstracts and obtained the full-text
reports of 19 references for further assessment. We included five
reports of five studies (Averbuch-Heller 1997; Kalla 2011; Lee
1994; Strupp 2003; Thiagarajan 2014) andwe excluded 14 studies
(see Characteristics of excluded studies for details). We did not
identify any ongoing studies from our searches of the clinical trials
registries.
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Figure 1. Study flow diagram
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Included studies
We included five trials which are summarised below. Additional
details can be found in the Characteristics of included studies
tables.
Averbuch-Heller 1997 randomised 21 participants (10 females
and 11 males) aged 25 to 73 years. There were 15 cases of ac-
quired pendular nystagmus and six of jerk nystagmus. The trial
was conducted across four sites in the USA and Germany. It was a
double-masked randomised controlled trial with a cross-over de-
sign, which compared two pharmacological interventions: 10 mg
baclofen and 30 mg gabapentin. Drug 1 was taken for two weeks,
followed by a wash-out period of two weeks; and drug 2 was then
taken for two weeks (six-week study duration in total). The par-
ticipant group was considered homogenous in that they had both
interventions. There were no exclusions, but one participant was
lost to follow-up. Outcomes weremeasured at baseline and at two-
, four- and six-week follow-up periods. They included measure-
ment of Landolt C visual acuity, eye movement recordings, sub-
jective image motion, adverse drug effect reporting and choice of
continued treatment. Inclusion criteria were specified, but not ex-
clusion criteria.
Kalla 2011 randomised eight participants (six females and two
males) with acquired downbeat nystagmus, aged 58 to 76 years.
The trial was conducted at one site in Germany. It was a dou-
ble-masked randomised controlled trial with a cross-over design,
which compared two pharmacological interventions: 4-aminopy-
ridine at a 10 mg dose and 3,4-diaminopyridine at a 10 mg dose.
Drug 1 was taken for one day, followed by a wash-out period of
six days; and Drug 2 was taken for one day (eight-day study du-
ration in total). The participant group was considered homoge-
nous in that they had both interventions. There were no exclusions
or losses to follow-up. Outcomes included measurement of 3D
video-oculography and participant recall of medical side effects.
Inclusion criteria were specified, but not exclusion criteria.
Lee 1994 recruited and randomised 54 people presenting with
acute unilateral sixth nerve palsy. Forty-seven participants were
followed up. There two groups: those receiving botulinum toxin
(Dysport™) to the isolateral medial rectus muscle (22 partici-
pants), and those observed for recovery with no invasive treatment
(25 participants). This trial was conducted at one site in the UK.
The intervention arm comprised 13 males and 9 females, with a
mean age of 63 years (range: 24 to 83). The control arm com-
prised 12 males and 13 females with a mean age of 61 years (range
24 to 86). This was a parallel design randomised controlled trial.
Outcome measurements included range of ocular movements for
abduction defect, angle of deviation measured by prism cover test,
and field of binocular single vision. These groups were compared
to each other for clinical diagnosis of recovery. A full recovery
was defined as completely normal ocular rotations with full field
of binocular single vision. Stable recovery was defined as normal
binocular single vision with a minor asymptomatic abduction de-
fect or a small asymptomatic vertical deviation. Non-recovery was
defined as a persisting esotropia in primary position with diplopia
not controllable by normal amplitudes of fusional vergence. Two
control participants were excluded due to change of diagnosis and
four were lost to follow-up. One participant from the botulinum
toxin group was lost to follow-up. Follow-up ranged from 4 to
42 months. Both groups were considered homogenous as gender,
age range, aetiology of sixth nerve palsy, duration of symptoms
and laterality of palsy were similar across both groups. The mean
deviation of control participants was 17.8 prism dioptres (PD);
for botulinum toxin participants this was 28.6 PD. The difference
in deviation across both groups was significant (P = 0.02). Three
of the 22 participants who received botulinum toxin injection had
one repeat injection.
Strupp 2003 recruited 18 participants with acquired downbeat
nystagmus (nine females and nine males) aged 50 to 85 years.
One person was subsequently excluded due to alcohol misuse.
The trial was conducted at one site in Germany. This was a dou-
ble-masked randomised controlled trial with a cross-over design,
which compared one pharmacological intervention with placebo
(3,4-Diaminopyridine at 20 mg dose versus lactose). Drug 1 was
taken for one day, followed by a wash-out period of more than one
week; and Drug 2 was taken for one day (nine-day study duration
in total). The participant group was considered homogenous in
that they had both interventions. There was one exclusion (due
to alcohol abuse), but no loss to follow-up. Outcomes included
measurement at baseline and follow-up of 2D video-oculography
and participant reports of oscillopsia and recall of medical side
effects. Inclusion and exclusion criteria were specified.
Thiagarajan 2014 randomised 12 participants withmild traumatic
brain injury which happened more than one year previously. Par-
ticipants aged on average 29 ± 3 years. The trial was conducted
at one site in the USA. It was a single-masked randomised con-
trolled trial with a cross-over design, which compared oculomo-
tor rehabilitation versus sham treatment. Oculomotor treatment
involved two sessions per week, each session lasting 60 minutes.
Participants were provided with training of version and vergence
eye movements and accommodation for 15 minutes each, inter-
spersed with five-minute rest periods. Sham treatment involved
two sessions of basic reading tasks per week, each session lasting 60
minutes. Each treatment was delivered for a period of six weeks,
with a one-week washout period between treatments and after the
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second treatment. The participant group was considered homoge-
nous in that they had both interventions. There were no exclu-
sions or losses to follow-up. Outcomes were measured at base-
line, after the first treatment block and after the second treatment
block. They included infrared eye recording of reading eye move-
ments, measurement of reading rate, saccadic ratio, near point of
convergence, binocular accommodative amplitude and use of the
convergence insufficiency symptom scale questionnaire. Inclusion
and exclusion criteria were specified.
Excluded studies
We excluded 14 studies (Barton 1994; Cifu 2014; Claassen 2013;
Clement 2007; Dai 2003; Feil 2013; Gur 1992; Leigh 1991;
Leivo 1996; Lorenz 2006; Metz 1988; Sharpe 2005; Strupp
2008; Zampieri 2009). For reasons of exclusion, please see the
Characteristics of excluded studies table. Main reasons for exclu-
sion were that the studies included conditions that were listed in
our exclusion criteria such as multiple sclerosis and degenerative
conditions, or that studies were not RCTs.
Risk of bias in included studies
See Figure 2; Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Allocation
Sequence generation was unclear in two trials (Averbuch-Heller
1997; Kalla 2011). It was evident that randomisation had occurred
but the method was not stated. One study (Lee 1994) specified
the use of a random number table; another (Strupp 2003) used a
computer-generated randomisation list; and a third (Thiagarajan
2014) used odd/even number randomisation for sequence gener-
ation. We considered these three trials to have low risk of bias for
this domain.
Adequate prevention of knowledge of the allocated interventions
was achieved in three trials (Averbuch-Heller 1997; Kalla 2011;
Strupp 2003). These trials used double-masked designs, with in-
vestigators and participants masked to the allocation of interven-
tions. We judged that allocation concealment did not take place
in the other two studies (Lee 1994; Thiagarajan 2014).
Blinding
Masking of participants and personnel:
Adequate prevention of knowledge of the allocated interventions
was achieved in three trials (Averbuch-Heller 1997; Kalla 2011;
Strupp 2003). These trials used double-masked designs, with in-
vestigators and participants masked to the allocation of interven-
tions. There was no masking (blinding) of investigators or par-
ticipants in the other two trials (Lee 1994; Thiagarajan 2014).
We judged Lee 1994 to be at high risk of both performance and
detection bias. Thiagarajan 2014 was single-masked (participants
were masked to the intervention) but all testing and training was
delivered by one investigator. We were less sure as to the extent
to which this lack of masking would create performance bias that
was independent of the effect of the intervention.
Masking of outcome assessors:
Adequate prevention of knowledge of the allocated interventions
was achieved in three trials (Averbuch-Heller 1997; Kalla 2011;
Strupp 2003) in which the outcome assessors were masked to the
allocation of interventions. There was no masking of outcome
assessors for the remaining studies (Lee 1994; Thiagarajan 2014).
Incomplete outcome data
Incomplete outcome data was adequately addressed in all four
trials, for which a low risk of bias was determined. All partici-
pants were accounted for throughout each trial, with outcome data
provided for participants completing the trials and information
provided for any participants lost to follow-up or excluded. One
study (Averbuch-Heller 1997) reported one person lost to follow-
up and this participant was removed from analysis, with follow-
up equal across groups. One study (Strupp 2003) excluded one
participant and removed the related results from analysis, with
follow-up equal across groups. In Lee 1994, follow-up was clearly
described and most participants were followed up (47/54, 87%).
However, loss to follow-up appeared to occur predominantly in
the control group. It is unclear whether this could have impacted
a comparison between control and intervention groups.
Selective reporting
It was difficult to reliably judge the extent of selective reporting
due to lack of published protocols and the fact the trials were
unregistered. Complicated analyses may also have been subject to
selective reporting.
Other potential sources of bias
We considered the following additional sources of bias for cross-
over studies.
Was the cross-over design suitable?
We judged the trials of pharmacological interventions possibly
suitable for cross-over design but the oculomotor rehabilitation
study (Thiagarajan 2014) we were less sure that this was suitable
as the training received at the first phase may influence the second
phase.
Was there a carry-over effect?
Possibly not in the drug trials where there was a washout phase but
this was unclear because none of the studies addressed this issue
directly.
Was only first period data are available?
Data were not reported fully and so neither first nor second period
data were available.
Was the analysis correct?
This was difficult to judge. None of the studies reported appro-
priate effect estimates and standard error which would have per-
mitted analysis in this review. One study reported findings for the
intervention group only (Thiagarajan 2014).
Comparability of results with those from parallel-group
trials
There was no overlap in cross-over and parallel-group trials.
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Effects of interventions
See: Summary of findings for the main comparison
Botulinum toxin versus observation; Summary of findings 2
Pharmacological treatment
Given the differences between studies, it was not possible to pro-
vide a meta analysis of results. Each study is discussed individually.
Restitutive interventions
We did not identify any relevant studies of restitutive interven-
tions.
Substitutive interventions
We identified one trial of botulinum toxin compared with ob-
servation for acute sixth nerve palsy (Lee 1994); see Summary of
findings for the main comparison.
Improvement in ocular motlity / Achievement of binocular
single vision
At four months after entry into the trial, Lee 1994 reported full
recovery with reduction in angle of deviation within 10 prism
dioptres in 21/22 (95%) participants given botulinum toxin and
20/25 (80%) of control participants (risk ratio 1.19, 95% CI 0.96
to 1.48; number of participants (n) = 47; Table 1). These same
participants also achieved binocular single vision. We judged the
certainty of evidence as low, downgrading for risk of bias and im-
precision. It was not possible to mask investigators or participants
to allocation and there was variable follow-up between groups.
Adverse effects
In the injection group only, there were cases of transient ptosis in
2/22 (9%) of participants, and transient vertical deviation in 4/22
(18%). In total the risk of complications per injection was 24%
and the risk of complications per participant was 27%.
Quality of life / Improvement in functional ability
The study did not report on functional ability and quality of life.
Compensatory interventions
We identified one cross-over trial of a compensatory intervention (
Thiagarajan 2014). This trial compared oculomotor rehabilitation
with sham training in 12 people with mild traumatic brain injury
(Table 2). We have some doubts as to whether a cross-over study
design is appropriate since this is an intervention that may have a
permanent effect, i.e. there may be an interaction between phase
and effect. The data were not analysed in a way that permitted
analysis of phase 1 only. The cross-over study design appeared to
be ignored in the analysis.
Improvement in ocular motility
With these caveats in mind, the study reported a drop in mean
saccade ratio with oculomotor rehabilitation from a mean value
of 2.1 to 1.7. This change was reported to be statistically signifi-
cant (P < 0.05). The saccade ratio was defined as the number of
tracking saccades executed divided by the number of test target
step displacements, with a ratio of 1 being optimal. The saccade
ratio was tested on single and multiple lines. The drop in reading
single lines was from 2.7 to 2.2 but this change reported as not
statistically significant (no P value reported).
Improvement in functional ability
Reading rate (words per minute) increased with oculomotor re-
habilitation from 142 (standard deviation (SD) 10) to 177 (SD
14) (P < 0.01). Reading levels increased by two grades, from 4.1
(SD 0.7) before oculomotor training to 6.3 (SD1.2) after training.
There was also a reduced number of fixations per 100 words, from
164 (SD10) to 135 (SD11). Binocular accommodative amplitude
and near point of convergence improved, alongside a reduction in
near fixation symptoms.
Data from the sham training group were not reported but it was
stated that the change in parameters was non-significant.
Achievement of binocular single vision / Quality of life /
Adverse effects
This study did not report on binocular single vision, quality of life
or adverse effects.
Summary
We considered this evidence to be very low-certainty. We down-
graded by two levels because of the study limitations described
above, in particular the limitations of a cross-over study design for
this intervention, and the lack of data reported from the control
(no intervention) group. We downgraded by one level for impre-
cision due to the small number of participants.
Pharmacological interventions
See Summary of findings 2.
We identified three cross-over studies of pharmacological inter-
ventions (Averbuch-Heller 1997; Kalla 2011; Strupp 2003).
These studies investigated two classes of pharmacological inter-
ventions: GABAergic drugs (gabapentin; baclofen) and aminopy-
ridines (4-aminopyridines (AP); 3,4-diaminopyridine (DAP)).
One study compared gabapentin and baclofen (Averbuch-Heller
1997, n = 21); one study compared 3,4-DAPwith placebo (Strupp
2003, n = 17); and one study compared 4-APwith 3,4-DAP (Kalla
2011, n = 8).
The results are summarised in Table 3.
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Gabapentin versus baclofen
Improvement in ocular motility
Averbuch-Heller 1997 included 21 participants but reported re-
sults separately for acquired pendular nystagmus (n = 15) and jerk
nystagmus (n = 6). It was difficult to extract data on comparative
effectiveness from the study report, as the data were only reported
in scatter plots separately by intervention and comparator. We
have to rely on the authors’ statements in the text which were as
follows:
Pendular nystagmus
• “...median eye speed was reduced in all three planes by
gabapentin, during viewing of the near or far targets; the effects
were similar in darkness. The predominant frequency of
oscillation was reduced, on average, by less than 9% by
gabapentin, but this reduction was consistent and statistically
significant (P < 0.05) in the horizontal and vertical planes during
viewing of far and near visual targets.”
• “...median eye speed was reduced significantly (P < 0.005)
only in the vertical plane by baclofen. Baclofen produced no
significant changes in the predominant frequency of APN.”
• “Neither drug caused any significant change in the gain of
saccades, smooth pursuit or the VOR [vestibulo-ocular reflex], or
changes in saccadic velocity, or conjugacy, similar to reported
effects in normal subjects. This was the case even in those
patients who showed substantial reduction of nystagmus with
gabapentin.”
Jerk nystagmus
• “For this group of patients, neither drug produced a
significant change in median, slow-phase eye speed. Changes in
individual patients depended on whether they viewed the near or
far targets.”
As there were fewer participants in this group, it is difficult to
know whether the lack of statistical significance was attributable
to a different effect in this subgroup or to the different number of
participants. Results for individual participants were reported but
these are difficult to interpret.
Achievement of binocular single vision
This was not reported but the results of the visual acuity tests were
as follows.
Pendular nystagmus
• “...there was a significant (P < 0.006) improvement of visual
acuity with gabapentin; this improvement was greater during
testing with the near card.”
• “...baclofen produced no significant change in visual acuity
measured at near or at far.”
Jerk nystagmus
• “... neither drug produced a significant change in visual
acuity.”
Reduction in participant-reported symptoms
Results for oscillopsia were as follows.
Pendular nystagmus
• “Twelve patients reported some illusory motion of the
visual target before treatment, and gabapentin reduced this
oscillopsia in 6.”
• “...Baclofen changed the direction of oscillopsia, without
reducing it, in 2 patients.”
Jerk nystagmus
• “Four patients reported some illusory motion of the visual
target before treatment; neither drug influenced oscillopsia in 4.”
Quality of life
This outcome was not reported but ten participants with pendular
nystagmus chose to continue treatment with gabapentin and one
chose to continue treatment with baclofen. Two participants with
jerk nystagmus chose to continue treatment with gabapentin and
one chose to continue with baclofen.
Adverse effects
No significant adverse events were reported. Drug intolerance was
reported in one person in the gabapentin group and four partic-
ipants in the baclofen group. Adverse events of increased ataxia
were reported in three participants in the gabapentin group and
two participants in the baclofen group.
Improvement in functional ability
This outcome was not reported.
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Summary
This study provides very low-certainty evidence that gabapentin
is better than baclofen and that these effects may be different in
pendular and jerk nystagmus. The data reported by this study did
not allow us to estimate the size of the effect. The lack of a formal
subgroup analysis means that it is unclear if the difference between
the two types of nystagmus may be a chance finding. The evidence
is low-certainty because of the small numbers of participants (for
which we downgraded by two levels for imprecision) and risk of
bias (it was a cross-over study with analysis that did not permit
estimation of effect size).
3,4-diaminopyridine versus placebo
One study (Strupp 2003) compared 3,4-DAP (20 mg) with
placebo (lactose) in 17 people with downbeat nystagmus. Assess-
ments were made 30 minutes after taking the drug. Comparative
measures of effect were not reported, and could not be calculated
with the information given, but statistical tests accounted for the
cross-over design (by two-way analysis of variance).
Improvement in ocular motility
In the 3,4-DAP group there was a reduction in mean peak slow-
phase velocity from 7.2 degrees/second (SD 4.2) to 3.1 degrees/
second (SD 2.5), which is considered clinically important. There
was no change in the lactose group (7.4 degrees/second (SD4.1) to
7.3 decrees/second (SD 3.7)). This difference between the groups
was reported to be statistically significant (P < 0.001).
Reduction in participant-reported symptoms
The authors report that in 10 of the 17 participants, mean peak
slow-phase velocity decreased by more than 50%. These 10 people
also reported having less oscillopsia.
Adverse effects
No significant adverse events were reported. Nine participants
continued treatment. Three participants reported transient side
effects of minor perioral/distal paraesthesia.
Outcomes not reported
• Achievement of binocular single vision
• Improvement in functional ability
• Quality of life
Summary
This study provides very low-certainty evidence that 3,4-DAPmay
reduce the mean peak slow-phase velocity in people with down-
beat nystagmus. We judged the evidence to be very low-certainty
because of the small size of the study (for which we downgraded
by two levels for imprecision) and risk of bias (it was a cross-over
study with no comparative measure of effect reported).
4-aminopyridines versus 3,4-diaminopyridine
One study (Kalla 2011) compared 4-AP and 3,4-DAP (both given
as a single 10 mg dose) in eight people with downbeat nystagmus.
Assessments were made 45 and 90 minutes after drug administra-
tion. Comparative measures of effect were not reported, and could
not be calculated with the information given, but statistical tests
probably accounted for the cross-over design (“repeated measure-
ment analysis of variances”).
Improvement in ocular motility
The authors report the following.
• Mean slow-phase velocity decreased from 5.68 degrees/
second to: 3.29 degrees/second at 45 minutes, and 2.96 degrees/
second at 90 minutes in people who had taken 3,4-DAP (P <
0.01).
• Mean slow-phase velocity decreased from 6.04 degrees/
second to: 1.58 degrees/second at 45 minutes, and 1.21 degrees/
second at 90 minutes in people who had taken 4-AP (P <
0.00001).
• The difference between the two drugs at 45 and 90 minutes
was statistically significant (P < 0.05).
Adverse effects
“All 8 patients reported mild paraesthesias from 30 minutes to 2
hours after ingestion of both medications. No other side effects
were reported.”
Outcomes not reported
• Achievement of binocular single vision
• Reduction in participant-reported symptoms
• Improvement in functional ability
• Quality of life
Summary
This study provides low-certainty evidence that both 3,4-DAP
and 4-AP may reduce the mean slow-phase velocity in people
with downbeat nystagmus. This effect may be stronger with 4-AP.
We judged the evidence to be very low-certainty because of the
small size of the study (for which we downgraded by two levels
for imprecision) and risk of bias (it was a cross-over study with
analysis that did not permit estimation of effect size).
Timing of interventions
Three trials (Averbuch-Heller 1997; Kalla 2011; Strupp 2003) did
not specify the timing at which interventions were provided after
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onset of the nystagmus. Therefore the timing of intervention can-
not be classified as acute or long-term, and its effect in the treat-
ment of nystagmus cannot be determined. In Lee 1994, partici-
pants were recruited at acute presentation to hospital emergency
department. Effect of acute intervention can be considered for this
trial (see section 2 above). In Thiagarajan 2014, participants were
recruited at least one year post-incident to ensure that any subse-
quent changes during training were not secondary to any natural
recovery period (estimated by the authors as being up to six to
nine months post-incident). Effect of late-timed intervention can
be considered for this trial (see section 3 above).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Pharmacological treatments (Gabapent in / Baclofen / 3,4-DAP / 4-AP) for people with acquired nystagmus
Participant or population: people with acquired nystagmus
Setting: eye clinic
Intervention: pharmacological treatment
Comparison: placebo or other drugs
Comparison Main findings of participants
(studies)
Certainty of the evidence
(GRADE)
Gabapentin up to 900 mg/ day) versus ba-
clofen (up to 30 mg/ day)
Follow-up 2 weeks
Gabapentin may work better than baclofen
in improving ocular motility and reducing
part icipant-reported symptoms (oscillop-
sia). These ef fects may be dif ferent in pen-
dular and jerk nystagmus but there was no
formal subgroup analysis so it is unclear
if the dif ference between the two types of
nystagmus was a chance f inding. Quality
of lif e was not reported but ten part icipants
with pendular nystagmus chose to con-
t inue treatment with gabapent in and one
with baclofen. Two part icipants with jerk
nystagmus chose to cont inue treatment
with gabapent in and one with baclofen.
Drug intolerance was reported in one per-
son for gabapent in and four part icipants
for baclofen. Increased ataxia was re-
ported in three part icipants for gabapent in
and two part icipants for baclofen
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VERY LOW1
3,4-DAP (20 mg, single dose) versus
placebo.
Assessments made 30 minutes af ter tak-
ing the drug or placebo
3,4-DAP may reduce the mean peak slow-
phase velocity in people with downbeat
nystagmus. In 10 of the 17 part icipants,
mean peak slow-phase velocity decreased
by more than 50% and these 10 people
reported having less oscillopsia. No signif -
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icant adverse events were reported. Nine
part icipants cont inued treatment. Three
part icipants reported transient side ef fects
of m inor perioral/ distal paraesthesia
4-AP (10 mg, single dose) versus 3,4-DAP
(10 mg, single dose)
Assessments made at 45 and 90 minutes
af ter taking the drug
3,4 DAP and 4-AP may reduce mean slow-
phase velocity in people with downbeat
nystagmus. This ef fect may be stronger
with 4-AP. All part icipants reported mild
paraesthesias with both medicat ions
8
(1 RCT)
⊕©©©
VERY LOW1
GRADE Working Group grades of evidence
High-certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate-certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low-certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low-certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded two levels for imprecision (due to small number of part icipants) and one level for serious risk of bias (cross-
over study with analysis that did not permit est imation of ef fect size).
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D I S C U S S I O N
Summary of main results
Following acquired brain injury, a variety of eye movement disor-
ders may occur including: strabismus, ocular cranial nerve palsies,
supranuclear and internuclear gaze palsies, nystagmus, saccadic
and smooth pursuit palsies. The literature on interventions for
these eye movement disorders consists predominantly of retro-
spective studies, cohort studies and case series, which are useful
for describing various treatment options but do not allow the es-
timation of effect size for recommendations based on clinical and
cost effectiveness.
We found five randomised controlled trials (RCTs), with a total
of 116 participants, that were eligible for inclusion in this review.
These trials included conditions of acquired nystagmus, sixth cra-
nial nerve palsy and ocular motility defects induced by traumatic
brain injury. We did not identify any relevant studies of restitutive
interventions. In view of the differences between studies, it was
not possible to provide a meta analysis of results.
We identified one trial of a substitutive intervention for acute sixth
nerve palsy. At four months after entry into the trial, people given
botulinum toxin were more likely to make a full recovery (with
reduction in angle of deviation within 10 prism dioptres), com-
pared with observation (low-certainty evidence). These same par-
ticipants also achieved binocular single vision and had improved
visual symptoms. In the injection group only, there were cases of
transient ptosis in 2/22 (9%) of participants, and transient vertical
deviation in 4/22 (18%); and there was a total complication rate
of 24% per injection and 27% per participant. Functional ability
and quality of life were not reported. We judged the certainty of
evidence as low, downgrading for risk of bias and imprecision.
We identified one cross-over trial of a compensatory intervention.
This study took place in the USA. Oculomotor rehabilitation was
compared with sham training in 12 people with mild traumatic
brain injury at least one year post-incident.We judged the evidence
from this study to be very low-certainty. The study was small, data
for the sham training group were not fully reported, and it was
unclear if a cross-over study design was appropriate as this is an
intervention that may be expected to have a permanent effect.
We identified three cross-over studies of pharmacological interven-
tions, which tookplace inGermany and theUSA.These studies in-
vestigated two classes of pharmacological interventions: GABAer-
gic drugs (gabapentin, baclofen) and aminopyridines (4-aminopy-
ridines (AP), 3,4-diaminopyridine (DAP)). We judged the evi-
dence from all three studies as very low-certainty because of the
small numbers of participants (for which we downgraded two lev-
els for imprecision) and risk of bias (they were cross-over studies
with data reported in a way that precluded estimation of effect
size). One study compared gabapentin (up to 900 mg/day) and
baclofen (up to 30 mg/day) in 21 people with pendular and jerk
nystagmus and followed up to two weeks. This study provides very
low-certainty evidence that gabapentin is better than baclofen and
that these effects may be different in pendular and jerk nystagmus.
There was no formal subgroup analysis, so it is unclear whether
the difference between the two types of nystagmus was a chance
finding or not. No significant adverse events were reported. Drug
intolerance was reported in one person from the gabapentin group
and four participants from the baclofen group. Increased ataxia
were reported in three participants from the gabapentin group and
two participants from the baclofen group. One study compared
a single dose of 3,4-DAP (20mg) with placebo in 17 people with
downbeat nystagmus. Assessments were made 30 minutes after
taking the drug. This study provides very low-certainty evidence
that 3,4-DAP may reduce the mean peak slow-phase velocity in
people with downbeat nystagmus and this may be accompanied
by less oscillopsia. Three participants reported transient side ef-
fects of minor perioral/distal paraesthesia. One study compared a
single 10 mg dose of either 4-AP or 3,4-DAP, in eight people with
downbeat nystagmus. Assessments were made 45 and 90 minutes
after drug administration. This study provides very low-certainty
evidence that both 3,4-DAP and 4-APmay reduce the mean slow-
phase velocity in people with downbeat nystagmus. This effect
may be stronger with 4-AP.
Overall completeness and applicability of
evidence
Overall the evidence on interventions for eye movement disorders
due to acquired brain injury is not complete. We identified only
five relevant studies. These studies covered a heterogenous groupof
conditions and interventions. They had limitations in their design
which means that it is difficult to draw firm conclusions as to the
effects of the treatments studied. Furthermore, no informationwas
obtained on the cost of treatment or on measure of participant or
parent satisfaction relating to treatment options and effectiveness.
It was, however, possible to describe the outcome of treatment in
each trial and ascertain the occurrence of adverse events.
Certainty of the evidence
We judged the certainty of evidence for all outcomes to be very
low or low primarily due to risk of bias in the included studies
and imprecise effect estimates. Four of the five studies had a cross-
over design but relevant estimates of effect from an appropriate
analyses were not reported in these studies. The included studies
were small.
Potential biases in the review process
We included five trials in this review. There may be a risk of publi-
cation bias regarding other conducted, but not registered or pub-
lished, trials. We systematically searched the available literature
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and did not identify further completed trials meeting our inclu-
sion criteria.
We made some modifications to the protocol but none of these
were likely to bias the results of the review. The protocol amend-
ments are specified in Differences between protocol and review.
Themajority of the changes relate tomethods that were not imple-
mented because of a lack of data. The main qualitative change we
implemented was to consider the different types of interventions
separately. It is unlikely that this introduced bias, particularly as
the data precluded formal meta-analysis. Other modifications in-
cluded preparing a summary of findings table and GRADE assess-
ment, as required by updated Cochrane methods. All outcomes
pre-specified in the protocol were included in the summary of
findings table.
Agreements and disagreements with other
studies or reviews
Similar results to those in this systematic review were reported in
another Cochrane systematic review on interventions for disorders
of eyemovement in participants with stroke (Pollock 2011). Their
review included two trials of pharmacological treatment for nys-
tagmus fromwhich they concluded there was insufficient evidence
to reach conclusions about the effectiveness of interventions for
participants with eye movement disorders after stroke, and they
recommended further high-quality research. Three of the five tri-
als included in our systematic review were also trials of pharmaco-
logical treatments for nystagmus. We also found insufficient high-
quality evidence for the treatment of eye movement disorders due
to acquired brain injury.
There have been two recent reviews of the role of botulinum toxin
in infantile esotropia (Issaho 2017) and strabismus (Mahan 2017).
In both reviews only non-comparative and non-randomised com-
parative studies were included, which would not have been eligi-
ble for the current review. Both reviews concluded that the overall
success rate of botulinum toxin in these groups of patients was
70% to 80%.
It is important to acknowledge that certain interventions do not
warrant randomised controlled trials to prove their effectiveness.
For example, Fresnel prisms are an established intervention for
correction of double vision (diplopia). These are temporary plastic
press-on prisms that can be applied to spectacles and are used in
selected cases of diplopia to correct the misalignment of the eyes
that causes this symptom (Gunton 2012; Haller 2014). Although
not a restorative treatment, these prisms alleviate the symptom
of diplopia and are a clinical and cost-effective treatment option;
and, likely, unethical to withhold as a treatment option. However,
for persistent eye movement problems requiring long-term man-
agement, further high-quality randomised controlled trials are re-
quired of the various options for pharmacological and surgical
treatment of eye movement disorders.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We were unable to fully address the aims and objectives of this
review due to the limited number of trials identified, the low to
very low-certainty evidence, and the variations in the conditions
being treated. Gabapentin and 4-aminopyridine may reduce os-
cillatory eye movements and improve visual acuity and partici-
pant-reported symptoms. Botulinum toxin may improve partici-
pant symptoms earlier than observation in people with sixth nerve
palsy. Very low-certainty evidence on oculomotor rehabilitation
suggested improved reading ability, binocular accommodation ap-
titude and near point of convergence in comparison to sham train-
ing. Adverse events these were specific to the interventions but
were mainly mild and transient.
Implications for research
There is a clear need for good quality trials to be conducted in
order to improve the evidence base for restitutive, substitutive,
compensatory and pharmacological therapies for eye movement
disorders following acquired brain injury. Further research is also
required to consider the effect of acute versus long-term timing of
interventions for these conditions.
Standardisation of research design and core outcome measures is
of importance taking into consideration the types and dosages of
drugs. Key characteristics for a future trial would be: adequate sam-
ple size based on sound estimates of clinically meaningful effect
size;multi-centre recruitment sites; computer-generated randomi-
sation schedule with concealed allocation; use of a core outcome
set and measures (COMET-initiative); a double-masked trial de-
sign when possible (i.e. appropriate masking of participants and
trial personnel); published protocol; and full outcome reporting
following a pre-determined statistical analysis plan.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Averbuch-Heller 1997
Methods Pharmacological interventions for acquired pendular and jerk nystagmus
Allocation: double-masked
Masking: double-masked
Exclusions: 0
Losses: 1
Design: cross-over RCT
Participants Country: 4 sites in USA and Germany
Number of participants randomised: 21 (15 with pendular nystagmus and 6 with jerk
nystagmus)
Age: 25-73 years
Gender: 10 female, 11 male
Aetiologies: multiple sclerosis (9), degeneration (1), cerebellar atrophy (1), stroke (5),
idiopathic (2), encephalitis (1), tonsillar herniation (1), AIDS (1)
Ocularmotility condition: acquired pendular nystagmus and horizontal jerk nystagmus
Inclusion criteria: adult nystagmus
Exclusion criteria: not specified
Interventions Intervention 1: gabapentin
Dose: 300 mg up to 900 mg/day
Intervention 2: baclofen
Dose: 10 mg up to 30 mg/day
Duration: 2 weeks of intervention, 1-2 weeks for wash-out period, 2 weeks of interven-
tion
Outcomes Measurements:
Landolt C, eye movement recordings, perceived motion of target, drug effects by partic-
ipant recall
Timepoints:
Baseline, 2 weeks, 4 weeks and 6 weeks
Adverse events:
Drug intolerance, Increased ataxia
Notes Health economic costs: not reported
Quality of life measures: not reported
Funding: USPHS grant E706717, Office of Research and development, Medical re-
search Service, Department of Veteran Affairs and Evenon Arlington Fund andDeutsche
Forschungsgemeinschaft
Declaration of interests: Parke-Davis Co provided transport and participant insurance
fees in Germany
Dates of study: not specified
Trial registration ID: not specified
Risk of bias
27Interventions for eye movement disorders due to acquired brain injury (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Averbuch-Heller 1997 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Low risk Quote: “Patients were randomly assigned
to [gabapentin or baclofen]; these drugs
were administered in opaque capsules that
were identical in appearance, and both the
primary investigators and the patients were
blinded as to their identify”
Judgment comment: primary investigators
were masked which suggests that the allo-
cation was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients were randomly assigned
to [gabapentin or baclofen]; these drugs
were administered in opaque capsules that
were identical in appearance, and both the
primary investigators and the patients were
blinded as to their identify”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Patients were randomly assigned
to [gabapentin or baclofen]; these drugs
were administered in opaque capsules that
were identical in appearance, and both the
primary investigators and the patients were
blinded as to their identify”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 21 people were recruited and 20 completed
both 2-week test periods. The one person
who dropped out did so because of an un-
related condition
Selective reporting (reporting bias) Unclear risk No access to study protocol or trials registry
entry.
Other bias High risk Additional ’Risk of bias’ assessment for
cross-over study
Was the cross-over design suitable: proba-
bly
Was there a carry-over effect: uncertain, no
analysis done.
Was only first period data available: no, first
period data were not available
Was the analysis correct: unclear, no esti-
mates of effect reported
Comparability of results with those from
parallel-group trials: no parallel group trials
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Kalla 2011
Methods Pharmacological interventions for acquired downbeat nystagmus
Allocation: double-masked
Masking: double-masked
Exclusions: 0
Losses: 0
Design: cross-over RCT
Participants Country: Germany
Number of participants randomised: 8
Age: mean 68 years ± 5.93, 58-76 years
Gender: 6 females, 2 males
Aetiologies: degeneration (2), Arnold-Chiari malformation (1), cryptogenic cerebellar
ataxia (4), inflammation (1)
Ocular motility condition: downbeat nystagmus
Inclusion criteria: adult nystagmus
Exclusion criteria: not specified
Interventions Intervention 1: 4-aminopyridine
Dose: 10 mg
Intervention 2: 3,4-diaminopyridine
Dose: 10 mg
Duration: 1 day for intervention with 6-day wash-out period between interventions
Outcomes Measurements:
3D video-oculography, drug effects by participant recall
Adverse events:
Mild paraesthesia
Notes Health economic costs: not reported
Quality of life measures: not reported
Funding: German Ministry of Education and Research
Declaration of interests: authors declare no conflicts of interest
Dates of study: not specified
Trial registration ID: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomly assigned
capsules of 10 mg of 3,4-DAP or 4-AP;
they received 1 single capsule of either sub-
stance. There was a washout period of 6
days when no medication was given. One
week later, the treatment was switched (i.e.
, they received a single capsule of the other
substance).”
Judgement comment: it was not reported
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Kalla 2011 (Continued)
how the allocation sequence was generated
Allocation concealment (selection bias) Low risk Judgement comment: study was described
as “double-blind” and identical single 10
mg doses used so we judge it was likely that
the allocation was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “...identical single 10-mg doses of
both aminopyridines were compared in our
double-blind study with crossover design”
Judgement comment: although this infor-
mation was only provided in the discussion
section of the article we judge that masking
of participants was likely to have been done
with identical tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “...identical single 10-mg doses of
both aminopyridines were compared in our
double-blind study with crossover design”
Judgement comment: although this infor-
mation was only provided in the discussion
section of the article we judge that masking
of outcome assessors was likely to have been
done with identical tablets and description
of the study as double-masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk Judgement comment: the article describes
a study of 8 patients. Loss to follow-up was
not mentioned
Selective reporting (reporting bias) Unclear risk No access to study protocol or trials registry
entry.
Other bias High risk Additional ’Risk of bias’ assessment for
cross-over study
Was the cross-over design suitable: proba-
bly
Was there a carry-over effect: uncertain, no
analysis done.
Was only first period data are available: no,
first period data not available
Was the analysis correct: unclear, no esti-
mates of effect reported
Comparability of results with those from
parallel-group trials: no parallel group trials
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Lee 1994
Methods Botulinum toxin versus observation of acute onset sixth nerve palsy
Allocation: random number table
Masking: not achieved
Exclusions: 2 due to change in diagnosis
Losses: 5 lost to follow-up
Study design: parallel RCT
Participants Country: UK
Number of participants randomised: 54 participants (54 eyes), 22 in BT group and
25 in control group
Dates of recruitment: August 1989 to August 1992
Age:
Controls: mean 61 years (24-86 years)
BT: mean 63 years (24-83 years)
Gender:
Controls: 12 male, 13 female
BT: 13 male, 9 female
Aetiologies:
Controls: multiple sclerosis (2) microvascular (16), sarcoidosis (1), ectatic basilar artery
(1), unknown (5)
BT: multiple sclerosis (1), microvascular (18), unknown (3)
Inclusion criteria: A & E walk-in - adult sixth nerve palsy
Exclusion criteria: change in diagnosis
Duration of symptoms:
Controls: ≤ 1 week in 17, ≤ 2 weeks in 6, 3 weeks in 1 and 4 weeks in 1
BT: ≤ 1 week in 7, ≤ 2 weeks in 9, ≤ 3 weeks in 5 and 6 weeks in 1
Angle of deviation:
Controls: primary position at distance fixation fixing with nonparetic eye; mean 17.8
PD (4 to 40 PD)
BT: primary position at distance fixation fixing with nonparetic eye; mean 28.6 PD (6
to 70 PD)
Repeat injections: undertaken in 3 participants
Interventions Treatment:
BT: 2.5 units Dysport™ to ipsilateral medial rectus muscle. 3 participants had a second
injection when first injection was inadequate
Control: observation
Duration: 4-42 months. Participants were followed up at 1 week, 6 weeks and 4 months
as a minimum and were discharged at 4 months if fully recovered.
Choice of eye for intervention: ipsilateral eye to the cranial nerve palsy - conventional
choice
Outcomes Measurements:
Ocular motility range - abduction deficit. Binary response of yes/no. Angle of deviation
by prism cover test. Field of binocular single vision. Participant-reported symptoms.
Adverse reactions
Notes Health economic costs: not reported
Quality of life measures: not reported
Funding: None specified
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Lee 1994 (Continued)
Declarations of interest: None specified
Trial registration number: None specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “...patients were randomly assigned
to ”treatment“ or ”control“ groups by ref-
erence to a random number table.”
Allocation concealment (selection bias) High risk Judgement comment: as the treatments
were quite different - botulinum toxin ver-
sus observation - it is likely that the Investi-
gators were aware of participant allocation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Judgement comment: as the treatments
were quite different - botulinum toxin ver-
sus observation - it is likely that the partic-
ipants and their carers were aware of par-
ticipant allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Judgement comment: as the treatments
were quite different - botulinum toxin ver-
sus observation - it is likely that the out-
come assessors were aware of participant al-
location
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote “Of the initial 54 patients, five (four
controls, one injection) were lost to follow-
up. A further two patients (both controls)
were later excluded because of a change in
diagnosis.”
Judgement comment: follow-upwas clearly
described and most participants were fol-
lowed-up (47/54, 87%). However, loss
to follow-up appeared to occur predomi-
nantly in the control group. It is unclear
what impact that would have had
Selective reporting (reporting bias) Unclear risk No access to study protocol or trials registry
entry.
Other bias Unclear risk Not applicable
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Strupp 2003
Methods Pharmacological interventions for acquired downbeat nystagmus
Allocation: double-masked
Masking: double-masked
Exclusions: 1 (chronic alcohol use)
Losses: 0
Design: cross-over RCT
Participants Country: Germany
Dates of recruitment: March 2002 to September 2002
Number of participants randomised: 18
Age: 50-85 years
Gender: 9 female, 9 male
Aetiologies: Arnold-Chiari malformation (1), degeneration (4), cerebellar ataxia (1),
stroke (3), unknown (8)
Ocular motility condition: acquired downbeat nystagmus
Inclusion criteria: pure downbeat nystagmus, downbeat nystagmus with associated
central vestibular or ocular motility disorders
Exclusion criteria: epileptic seizures, cardiac arrhythmia, taking drugs affecting the
central nervous system or vestibular system
Interventions Intervention: 3,4-diaminopyridine
Dose: 20 mg
Control: lactose placebo
Duration: 1 day of intervention, 1-2 weeks for wash-out period, 1 day of control
Outcomes Measurements:
2-dimensional video-oculography, perceivedmotion of target, drug effects by participant
recall
Timepoints:
Baseline, 1 day and 2 weeks
Adverse events:
Transient minor perioral or digital paraesthesia, nausea
Notes Health economic costs: not reported
Quality of life measures: not reported
Funding: not specified
Declaration of interests: not specified
Trial registration ID: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “With use of a computer-generated
randomization list”
Allocation concealment (selection bias) Low risk Quote: “Code envelopes were kept by the
investigator during the trial and returned
unopened to the monitor after termination
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Strupp 2003 (Continued)
of the study. The blind was maintained un-
til data analysis had been completed.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Capsules with 20 mg of 3,4-DAP
and lactose or placebo (a capsule with lac-
tose alone) were manufactured and deliv-
ered by the pharmacy of the University
of Munich (Klinikum Grosshadern). The
shape and color of the capsules with 3,4-
DAP or placebo were identical.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Capsules with 20 mg of 3,4-DAP
and lactose or placebo (a capsule with lac-
tose alone) were manufactured and deliv-
ered by the pharmacy of the University
of Munich (Klinikum Grosshadern). The
shape and color of the capsules with 3,4-
DAP or placebo were identical.”
Quote: “Code envelopes were kept by the
investigator during the trial and returned
unopened to the monitor after termination
of the study. The blind was maintained un-
til data analysis had been completed.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Seventeen patients (nine men;
aged 50 to 85 years) with DBN were in-
cluded in the study; one patient had to be
excluded because of chronic alcohol con-
sumption even on the day of the planned
examination”
Judgement comment: this excluded partic-
ipant appeared to be excluded before ran-
domisation. All 17 participants completed
the study
Selective reporting (reporting bias) Unclear risk No access to study protocol or trials registry
entry.
Other bias High risk Additional ’Risk of bias’ assessment for
cross-over study
Was the cross-over design suitable: proba-
bly
Was there a carry-over effect: uncertain, no
analysis done.
Was only first period data are available: no,
first period data not available
Was the analysis correct: unclear, no esti-
mates of effect reported
Comparability of results with those from
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Strupp 2003 (Continued)
parallel-group trials: no parallel group trials
Thiagarajan 2014
Methods Oculomotor rehabilitation versus sham training for traumatic brain injury
Allocation: single masked
Masking: single masked
Exclusions: 0
Losses: 0
Design: cross-over RCT
Participants Country: USA
Number of participants randomised: 12
Age: 29 ± 3 years
Gender: not specified
Aetiologies: type of acquired brain injury not specified
Ocular motility condition: any acquired disorder
Inclusion criteria:TBIonset at least one year post-incident to ensure that any subsequent
changes during training are not secondary to their natural neurological recovery function
period (6-9 months). Participants exhibit at least one symptom (e.g. skipping lines while
reading, blur, diplopia, etc.) and one clinical sign (e.g. receded near point of convergence)
of a non-strabismic oculomotor dysfunction related to impaired sustained reading. Intact
cognitive ability to perform the required tasks for the study. Stable systemic health
Exclusion criteria: persons over the age of 40 years, as they typically will not have
sufficient accommodation to measure reliably. Best corrected visual acuity poorer than
20/30 in either eye. Constant strabismus, amblyopia, or ocular disease in either eye.
Medications that alter oculomotor function or attentional state (or both)
Interventions Intervention: ocular motor rehabilitation - training of versions, vergence and accom-
modation for 15 minutes each interspaced with 5 minute rest intervals
Dose: 2 sessions of 60 minutes training per week, block of 6 weeks
Control: sham treatment of basic reading tasks
Dose: 2 sessions of 60 minutes training per week, block of 6 weeks
Duration: 2 blocks of 6 weeks with one-week interim wash-out
Outcomes Measurements:
Reading rate, infra-red eye recording of reading eye movements, saccade ratio - pro-
gression and regression saccades by eye movement recording, binocular accommodative
amplitude, near point of convergence, convergence insufficiency symptom survey ques-
tionnaire
Timepoints:
Baseline, 6 weeks and post final block
Notes Health economic costs: not reported
Funding: US Army, DoD award, College of Optometrists in Vision Development and
SUNY Graduate programme
Dates of study: not reported
Declaration of interests: no interests to declare
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Thiagarajan 2014 (Continued)
Trial registration ID: not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “During phase 1, every odd-num-
bered subject first receivedOMT, and every
even-numbered subject first received ST,
and vice-versa during phase 2.”
Allocation concealment (selection bias) High risk Single-masked
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “A cross-over, interventional exper-
imental design of a single-blinded nature
(for the subject) was used.”
Judgement comment: this implies the par-
ticipants were masked to the intervention,
but the intervention and control are so dif-
ferent it is likely that the participants may
be influenced by knowledge of the inter-
vention. It is unclear what the impact of
this would have been and may be consid-
ered to be part of the intervention so we
have graded this as unclear risk of bias
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not masked
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data
Selective reporting (reporting bias) Unclear risk No access to study protocol or trials registry
entry.
Other bias High risk Additional risk of bias assessment for
cross-over study
Was the cross-over design suitable: proba-
bly not
Was there a carry-over effect: uncertain, no
analysis done.
Was only first period data are available: no,
first period data not available
Was the analysis correct: unclear, no esti-
mates of effect reported, data for interven-
tion group only reported
Comparability of results with those from
parallel-group trials: no parallel group trials
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A & E: Accident and Emergency
AIDS: acquired immune deficiency syndrome
BT: botulinum toxin
PD: prism dioptre
RCT: randomised controlled trial
SEM: standard error mean
TBI: traumatic brain injury
USPHS: United States Public Health Service
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barton 1994 Six of seven cases were either multiple sclerosis or degenerative; only one case of potential acquired brain injury
Cifu 2014 Not a randomised controlled trial
Claassen 2013 25 of 27 cases were either idiopathic or degenerative; only two cases of potential acquired brain injury
Clement 2007 Cases were normal participants with induced vestibular imbalance; no acquired brain injury
Dai 2003 Cases were normal participants with induced imbalance; no acquired brain injury
Feil 2013 No cases of acquired brain injury; all participants were idiopathic or degenerative
Gur 1992 Not a randomised controlled trial
Leigh 1991 Seven of ten cases were either multiple sclerosis or degenerative; only three cases of acquired brain injury
Leivo 1996 Not a randomised controlled trial
Lorenz 2006 No cases of acquired brain injury; all with essential tremor
Metz 1988 Not a randomised controlled trial
Sharpe 2005 Not a randomised controlled trial
Strupp 2008 Not a randomised controlled trial
Zampieri 2009 No cases of acquired brain injury; all with progressive supranuclear palsy
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A D D I T I O N A L T A B L E S
Table 1. Botulinum toxin versus observation
Study ID Total participants Primary: improved
ocular motility
Secondary: improved
binocular single vision
Secondary: improved
symptoms
Secondary: adverse
events
Lee 1994 47, parallel arm RCT
22 - botulinum toxin
25 - observation
6 month follow-up
21 (95.5%) - bo-
tulinum toxin
20 (80%) - observa-
tion
Success:
21 (95.5%) - bo-
tulinum toxin
20 (80%) - observa-
tion
Partial:
3 (12%) - observation
Fail:
1 (4.5%) - botulinum
toxin
2 (8%) - observation
21 (95.5%) - bo-
tulinum toxin
20 (80%) - observa-
tion
9% ptosis
18%vertical deviation
RCT: randomised controlled trial
Table 2. Oculomotor rehabilitation versus sham training
Study ID Total participants Primary: improved
ocular motility
Secondary:
improved functional
vision
Secondary:
improved symptoms
Secondary: adverse
events
Thiagarajan 2014 12, cross-over RCT
13-week follow-up
Baseline 2.1 saccadic
ratio reducing to 1.
7, P < 0.05 - OM re-
habilitation
Control group
change not reported
Reading rate:
Baseline 142 (10)
wpm improving to
177 (14).
Reading level:
Baseline 4.1 (0.7)
grade level improv-
ing to 6.3 (1.2), P <
0.01
Fixations per 100
words:
Baseline 164 (10)
improving to 135
(11), P = 0.02
Regressions per 100
words:
Baseline 30 (3) im-
proving to 23 (4)
Con-
trol group changes
not reported
[means (SEM)]
Improved for OM
rehabilitation.
Con-
trol group changes
not reported
Nil reported
SEM: standard error mean
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OM: oculo motor
RCT: randomised controlled trial
WPM: words per minute
Table 3. Pharmacological treatment for nystagmus
Study ID Total participants Primary: improved
ocular motility
Secondary: im-
proved visual acuity
Secondary: im-
proved symptoms
Secondary: adverse
events
Averbuch-Heller
1997
21, crossover RCT
15 - pendular
6 - jerk
6-week trial dura-
tion
15 pendular -
gabapentin
15 pendular -
gabapentin
1 jerk - gabapentin
1 jerk - baclofen
6 pendular -
gabapentin
1 jerk - gabapentin
1 jerk - baclofen
1 drug intolerance -
gabapentin
4 drug intolerance -
baclofen
3 ataxia -
gabapentin
2 ataxia - baclofen
Kalla 2011 8, crossover RCT
8 - downbeat
8-day trial duration
Baseline -6.04; 45
mins -1.58; 90 mins
-1.21 (4-aminopyri-
dine)
Baseline -
5.68; 45mins -3.29;
90 mins -2.96 (3,4-
diaminopyridine)
- - All with mild
paraesthesia
Strupp 2003 17, crossover RCT
17 - downbeat
16-day trial dura-
tion
Baseline 7.2 ± 4.
2 °/sec reducing to
3.1 ± 2.5 (3,4-di-
aminopyridine)
Baseline 7.4 ± 4.1 °/
sec reducing to 7.3 ±
3.7 (placebo)
- 10 - reduced symp-
toms (3,4-
diaminopyridine)
0 - reduced symp-
toms (placebo)
3 - mild paraesthe-
sia (3,4-diaminopy-
ridine)
1 - nausea/headache
(3,4-
diaminopyridine)
RCT: randomised controlled trial
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Brain Injuries] explode all trees
#2 brain near/2 injur*
#3 ABI or TBI or non TB
#4 #1 or #2 or #3
#5 MeSH descriptor: [Eye] explode all trees
#6 MeSH descriptor: [Visually Impaired Persons] explode all trees
#7 MeSH descriptor: [Ocular Physiological Processes] explode all trees
#8 MeSH descriptor: [Diagnostic Techniques, Ophthalmological] explode all trees
#9 MeSH descriptor: [Optometry] explode all trees
#10 MeSH descriptor: [Orthoptics] explode all trees
#11 MeSH descriptor: [Eye Diseases] this term only
#12 MeSH descriptor: [Vision Disorders] this term only
#13 MeSH descriptor: [Eye Manifestations] this term only
#14 MeSH descriptor: [Blindness] this term only
#15 MeSH descriptor: [Diplopia] explode all trees
#16 MeSH descriptor: [Vision, Binocular] this term only
#17 MeSH descriptor: [Vision, Monocular] this term only
#18 MeSH descriptor: [Visual Acuity] explode all trees
#19 MeSH descriptor: [Visual Fields] this term only
#20 MeSH descriptor: [Vision, Low] this term only
#21 MeSH descriptor: [Visual Field Tests] explode all trees
#22 MeSH descriptor: [Ophthalmology] this term only
#23 MeSH descriptor: [Vision Screening] this term only
#24 MeSH descriptor: [Eye Diseases, Hereditary] explode all trees
#25 MeSH descriptor: [Ocular Motility Disorders] explode all trees
#26 MeSH descriptor: [Optic Nerve Diseases] explode all trees
#27 MeSH descriptor: [Orbital Diseases] explode all trees
#28 MeSH descriptor: [Pupil Disorders] explode all trees
#29 MeSH descriptor: [Refractive Errors] explode all trees
#30 MeSH descriptor: [Blindness, Cortical] explode all trees
#31 MeSH descriptor: [Hemianopsia] explode all trees
#32 MeSH descriptor: [Scotoma] this term only
#33 MeSH descriptor: [Abducens Nerve] this term only
#34 MeSH descriptor: [Oculomotor Nerve] this term only
#35 MeSH descriptor: [Trochlear Nerve] this term only
#36 “smooth pursuit” or saccades or saccadic or “depth perception” or stereopsis or gaze disorder* or ophthalm* or optic nerve*
#37 (downbeat or upbeat or vertical) near/3 nystagmus
#38 gaze* near/2 (deficit* or pals* or disorder*)
#39 ocular near/2 (muscle* or align*)
#40 esotropi* or exotropi* or hypertropi* or hypotropi* or cyclotropi*
#41 intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation
#42 (visual* or vision or eye or eyes or eyesight or sight) near/3 (problem* or disorder* or impair* or disabilit* or loss or disease* or
defect* or manifestation* or screening or test* or examination*)
#43 reading near/2 (difficult* or impair*)
#44 hemianop* or blindness or low vision or refractive errors or scotoma or diplopia or optometr* or ocular or orthoptic*
#45 oscillopsia or visual tracking or fresnel prism*
#46 III or IV or VI or third or fourth or sixth near/3 nerve palsy
#47 (#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #22 or #23 or #24
or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #41 or #42 or #44 or #45 or #46)
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#48 #4 and #47
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp brain injuries/
14. (brain adj2 injur$).tw.
15. (ABI or TBI or non TBI).tw.
16. or/13-15
17. exp Eye/
18. exp Visually Impaired Persons/
19. exp Ocular Physiological Processes/
20. exp Diagnostic Techniques, Ophthalmological/
21. exp Optometry/
22. exp Orthoptics/
23. exp Eye Diseases/
24. exp Vision Disorders/
25. exp Eye Manifestations/
26. exp Blindness/
27. exp Diplopia/
28. Vision, Binocular/
29. Vision, Monocular/
30. exp Visual Acuity/
31. Visual Fields/
32. Vision, Low/
33. exp Visual Field Tests/
34. Ophthalmology/
35. Vision Screening/
36. Eye Diseases, Hereditary/
37. exp Ocular Motility Disorders/
38. exp Optic Nerve Diseases/
39. Enophthalmos/
40. exp Pupil Disorders/
41. exp Refractive Errors/
42. Blindness, Cortical/
43. exp Hemianopsia/
44. Scotoma/
45. Abducens Nerve/
46. Oculomotor Nerve/
47. Trochlear Nerve/
48. (smooth pursuit or saccades or saccadic or depth perception or stereopsis or gaze disorder$ or ophthalm$ or optic nerve$).tw.
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49. (ocular adj2 (muscle$ or align$)).tw.
50. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
51. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
52. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
53. (reading adj2 (difficult$ or impair$)).tw.
54. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
55. (oscillopsia or visual tracking or fresnel prism$).tw.
56. or/17-55
57. 12 and 16 and 56
58. ((downbeat or upbeat or vertical) adj3 nystagmus).tw.
59. (gaze$ adj2 (deficit$ or pals$ or disorder$)).tw.
60. ((III or IV or VI or third or fourth or sixth) adj3 nerve pals$).tw.
61. or/58-60
62. 12 and 61
63. 57 or 62
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
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33. exp brain injury/
34. (brain adj2 injur$).tw.
35. (ABI or TBI or non TBI).tw.
36. or/33-35
37. eye/
38. visual system function/
39. visual system examination/
40. optometry/
41. orthoptics/
42. eye disease/
43. visual disorder/
44. exp eye movement disorder/
45. exp visual impairment/
46. exp vision/
47. perimetry/
48. ophthalmology/
49. exp optic nerve disease/
50. exp cranial nerve/
51. (smooth pursuit or saccades or saccadic or depth perception or stereopsis or gaze disorder$ or ophthalm$ or optic nerve$).tw.
52. (ocular adj2 (muscle$ or align$)).tw.
53. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
54. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
55. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
56. (reading adj2 (difficult$ or impair$)).tw.
57. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
58. (oscillopsia or visual tracking or fresnel prism$).tw.
59. or/37-58
60. 32 and 36 and 59
61. ((downbeat or upbeat or vertical) adj3 nystagmus).tw.
62. (gaze$ adj2 (deficit$ or pals$ or disorder$)).tw.
63. ((III or IV or VI or third or fourth or sixth) adj3 nerve pals$).tw.
64. or/61-63
65. 32 and 64
66. 60 or 65
Appendix 4. CINAHL EBSCO search strategy
S56 S12 AND S55
S55 S16 AND S54
S54 S51 or S52 or S53
S53 S41 or S42 or S43 or S44 or S45 or S46 or S47 or S48 or S49 or S50 or S51
S52 S31 or S32 or S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40
S51 S17 or S18 or S19 S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30
S50 nerve palsy
S49 oscillopsia or visual tracking or fresnel prism*
S48 hemianop* or blindness or low vision or refractive errors or scotoma or diplopia or optometr* or ocular or orthoptic*
S47 reading N2 (difficult* or impair*)
S46 (visual* or vision or eye or eyes or eyesight or sight) N5 (problem* or disorder* or impair* or disabilit* or loss or disease* or defect*
or manifestation* or screening or test* or examination*)
S45 intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation
S44 esotropi* or exotropi* or hypertropi* or hypotropi* or cyclotropi*
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S43 ocular N2 (muscle* or align*)
S42 gaze* N2 (deficit* or palsy or disorder*)
S41 nystagmus or smooth pursuit or saccades or depth perception or stereopsis or ophthalmol* or optic nerve
S40 (MH “Trochlear Nerve”) OR (MH “Trochlear Nerve Diseases”)
S39 (MH “Abducens Nerve Diseases+”) OR (MM “Abducens Nerve”)
S38 (MM “Refractive Errors+”)
S37 (MH “Pupil Disorders+”)
S36 (MH “Orbital Diseases+”)
S35 (MH “Optic Nerve Diseases+”)
S34 (MM “Ocular Motility Disorders”)
S33 (MM “Eye Diseases, Hereditary”)
S32 (MM “Ophthalmology”)
S31 (MH “Vision Tests+”)
S30 (MH “Visual Perception+”)
S29 (MM “Visual Fields”)
S28 (MH “Visual Acuity”)
S27 (MH “Depth Perception”)
S26 (MH “Vision, Subnormal”)
S25 (MM “Diplopia”)
S24 (MH “Blindness+”)
S23 (MH “Eye Manifestations+”)
S22 (MH “Vision Disorders+”)
S21 (MH “Eye Diseases+”)
S20 (MM “Optometry”)
S19 (MH “Diagnosis, Eye+”)
S18 (MH “Rehabilitation of Vision Impaired+”)
S17 (MH “Eye+”)
S16 S13 or S14 or S15
S15 ABI or TBI or non TBI
S14 brain N2 injur*
S13 (MH “Brain Injuries+”)
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TX allocat* random*
S10 (MM “Quantitative Studies”)
S9 (MM “Placebos”)
S8 TX placebo*
S7 TX random* allocat*
S6 (MM “Random Assignment”)
S5 TX randomi* control* trial*
S4 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl*
n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S3 TX clinic* n1 trial*
S2 PT Clinical trial
S1 (MH “Clinical Trials+”)
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Appendix 5. AMED Ovid search strategy
1. “Randomized controlled trials”/
2. prospective studies/
3. single blind method/
4. random$.tw.
5. placebo$.tw.
6. trial$.tw.
7. groups.tw.
8. ((singl$ or doubl$) adj3 (blind$ or mask$)).tw.
9. or/1-8
10. brain injuries/
11. (brain adj2 injur$).tw.
12. (ABI or TBI or non TBI).tw.
13. or/10-12
14. eye/
15. Blindness/
16. Vision disorders/
17. Vision/
18. Ocular Motility Disorders/
19. Eye Movements/
20. Optic nerve/
21. Refractive Errors/
22. Cranial nerves/
23. (smooth pursuit or saccades or saccadic or depth perception or stereopsis or gaze disorder$ or ophthalm$ or optic nerve$).tw.
24. (ocular adj2 (muscle$ or align$)).tw.
25. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
26. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
27. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
28. (reading adj2 (difficult$ or impair$)).tw.
29. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
30. (oscillopsia or visual tracking or fresnel prism$).tw.
31. or/14-30
32. 9 and 13 and 31
33. ((downbeat or upbeat or vertical) adj3 nystagmus).tw.
34. (gaze$ adj2 (deficit$ or pals$ or disorder$)).tw.
35. ((III or IV or VI or third or fourth or sixth) adj3 nerve palsy).tw.
36. or/33-35
37. 9 and 36
38 32 or 37
Appendix 6. PsychINFO Ovid search strategy
1. exp Treatment Effectiveness Evaluation/
2. exp Clinical Trials/
3. exp Placebo/
4. placebo$.tw.
5. randomly.tw.
6. randomi#ed.tw.
7. trial$.tw.
8. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).tw.
9. (factorial$ or allocat$ or assign$ or volunteer$).tw.
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10. (crossover$ or cross over$).tw.
11. (quasi adj (experimental or random$)).tw.
12. (control$ adj3 (trial$ or study or studies or group$)).tw.
13. or/1-12
14. exp Brain Damage/
15. exp Traumatic Brain Injury/
16. (ABI or TBI or non TB).tw.
17. exp Head Injuries/
18. or/14-17
19. exp Eye Disorders/
20. exp Eye Fixation/
21. exp “Pupil (Eye)”/
22. exp Vision Disorders/
23. exp Vision/
24. exp Blind/
25. exp Optometry/
26. exp Strabismus/
27. exp Amblyopia/
28. exp Binocular Vision/
29. exp Eye Convergence/
30. exp Color Perception/
31. exp Visual Acuity/
32. exp Visual Field/
33. exp Ophthalmology/
34. exp Ophthalmologic Examination/
35. exp Hemianopia/
36. exp Abducens Nerve/
37. exp Cranial Nerves/
38. (smooth pursuit or saccades or saccadic or depth perception or stereopsis or gaze disorder$ or ophthalm$ or optic nerve$).tw.
39. (ocular adj2 (muscle$ or align$)).tw.
40. (esotropi$ or exotropi$ or hypertropi$ or hypotropi$ or cyclotropi$).tw.
41. (intranuclear ophthalmoplegia or parinaud’s syndrome or weber’s syndrome or skew deviation or conjugate deviation).tw.
42. ((visual$ or vision or eye or eyes or eyesight or sight) adj3 (problem$ or disorder$ or impair$ or disabilit$ or loss or disease$ or
defect$ or manifestation$ or screening or test$ or examination$)).tw.
43. (reading adj2 (difficult$ or impair$)).tw.
44. (hemianop$ or blindness or low vision or refractive errors or scotoma or diplopia or optometr$ or ocular or orthoptic$).tw.
45. (oscillopsia or visual tracking or fresnel prism$).tw.
46. or/19-45
47. 13 and 18 and 46
48. ((downbeat or upbeat or vertical) adj3 nystagmus).tw.
49. (gaze$ adj2 (deficit$ or pals$ or disorder$)).tw.
50. ((III or IV or VI or third or fourth or sixth) adj3 nerve pals$).tw.
51. or/48-50
52. 13 and 51
53. 47 or 52
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Appendix 7. Dissertations and Theses (PQDT) database
Keywords (dissertation topic) = brain injury
Appendix 8. PsycBITE database
PsycBITE was searched using the following options from the search interface:
Neurological Group = Traumatic Brain Injury (TBI) /Head Injury
Method = Randomised Controlled Trials
Target area = Literacy/Numeracy OR Visual Field Loss OR Community Re-entry
Appendix 9. ISRCTN search strategy
brain Injury
nystagmus
gaze deficit
nerve palsy
Appendix 10. ClinicalTrials.gov search strategy
brain Injury OR nystagmus OR gaze deficit OR nerve palsy
Appendix 11. Health Services Research Projects in Progress
brain Injury
nystagmus
gaze deficit
nerve palsy
Appendix 12. National Eye Institute Clinical Studies Database
brain Injury
nystagmus
gaze deficit
nerve palsy
Appendix 13. WHO ICTRP search strategy
brain Injury
nystagmus
gaze deficit
nerve palsy
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Appendix 14. Standardised headings for included studies table
Headings in table in RevMan Proposed subheadings
Methods Study design • Parallel group RCT, i.e. people randomised to treatment
• Paired eye or intra-individual RCT, i.e. eyes randomised to
treatment
• Cluster RCT, i.e. communities randomised to treatment
• Cross-over RCT
• Other
Eyes • One eye included in study
◦ Indicating how the eye was selected
• Two eyes included in study, both eyes received same treatment
◦ Indicating how data were analysed (best/worst/average/
both) and adjusted for within person correlation/both and not
adjusted for within person correlation
◦ Indicating if a mixture of one eye and two eyes were used
• Two eyes included in study, eyes received different treatments
(pair matched)
◦ Indicating if a correct pair-matched analysis was done
Participants Country
Setting
Number of participants
Number of men
Number of women
Average age
Age range
Ethnic group
Inclusion criteria
Exclusion criteria
Eye movement disorders Description of the type of eye movement disorder (III, IV, and VI
cranial nerve palsy, reduced fixation, gaze holding, gaze palsy, saccadic
problems, smooth pursuit problems, strabismus, nystagmus, reduced
convergence or divergence, conjugate deviation, skew deviation), the
deviation of eye movement (horizontal, vertical, torsional), and the
severity of eye movement disorder (slight, small, moderate, marked;
paralysis, paresis; monocular, binocular)
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(Continued)
Acquired brain injury Description of type of brain injury, natural history, side of brain injury
Interventions Intervention
Comparator
We provide a description of interventions given to each treatment
group including, if relevant, the duration, intensity, frequency, or dose.
We classify the type of intervention as restitution, compensation, phar-
macological or substitution, type of brain injury, type of eyemovement
disorder, and the type of control as no treatment, placebo, control,
or standard care. We document the professional background of the
person providing the intervention (e.g. ophthalmologist, orthoptist)
Outcomes List We document the primary and secondary outcomes relevant to this
review as listed in the Types of outcome measures section. Specifi-
cally, we document measurements showing change in angle of devia-
tion and/or extent of eye movement range, measurement of binocular
single vision, documentation of participant-reported symptoms, doc-
umentation of questionnaires and adverse events. If a study has used
a number of different methods of measuring the same outcome (e.g.
prisms and degrees for measurement of ocular deviation), we note each
method to be used for any subsequent analysis
Notes Date conducted Indicating specific dates of recruitment of participants mm/yr to mm/
yr
Sources of funding
Declaration of interest Indicating any declarations of interest among the primary researchers
Other We record any important confounding variables. If a study includes
more than two intervention groups, we also record the method of
including these groups in any subsequent analysis
C O N T R I B U T I O N S O F A U T H O R S
FR proposed the review questions, co-ordinated the review, organised retrieval of papers and wrote to trial authors for additional
information.
FR and KH screened search results, screened retrieved papers against inclusion criteria, appraised quality of papers, extracted data from
papers, provided additional data about papers, obtained and screened data on unpublished studies and entered data in ReviewManager.
JE provided methodological expertise.
All authors provided additional content expertise, provided clinical, policy and consumer perspectives, read and commented on final
drafts of the review.
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D E C L A R A T I O N S O F I N T E R E S T
Fiona Rowe is an National Institute of Health Research (NIHR) Research Fellow and has received funding from the NIHR to support
research relating to visual problems after stroke (including this Cochrane Review).
The work presented here represents the view of the authors and not necessarily those of the funding bodies.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
• NIHR have funded the research fellowship programme that encompasses this Review.
• Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV
research sessions from the Department of Health through the award made by the NIHR to Moorfields Eye Hospital NHS
Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.
• This review was supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK editorial base.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews
Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Objectives
During the course of doing the review it became clear that it would not make sense to pool data on the pre-specified different types
of interventions (restitutive, substitutive, compensatory and pharmacological) as they are clinically so different. Our original protocol
objectives specified a primary objective which implied that these interventions would be pooled, if data were available. We amended
our objectives to make it clear that we considered these different groups of interventions separately.
Inclusion criteria
We clarified the following inclusion criteria.
• Type of studies: we clarified the inclusion of cross-over trials.
• Type of participants: we clarified the inclusion of studies of mixed aetiologies.
• Type of participants: we clarified the exclusion of participants with multiple sclerosis and degenerative conditions.
Search strategy
We amended the search strategy to include additional terms for nystagmus, nerve palsy and gaze disorders.
Amendment to methods
• Measures of treatment effect: we used the risk ratio rather than the odds ratio as planned, since this provides a better assessment
of the treatment effect. Odds ratios are always more exaggerated (larger or smaller) and in this review there were no analytical issues
that would warrant using the odds ratio.
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• Assessment of risk of bias: As four out of the five included studies were cross-over studies, we amended the protocol to include
additional ’Risk of bias’ assessment criteria for cross-over studies (Higgins 2011c).
• GRADE and ’Summary of findings’ table: these were not specified in the protocol but we added them because they have since
become mandatory Cochrane methods ( methods.cochrane.org/mecir).
Planned methods that were not used
• We did not undertake any meta-analyses so the following planned methods were not implemented.
• Measures of treatment effect: we specified the use of the standardised mean difference and also how we would manage change
data and final value data but this was not needed.
• Dealing with missing data: we planned to assess trials that included intention-to-treat analyses to ensure this had been done
correctly, ensuring participants had been included even if they did not fully adhere to the protocol and that it was possible to extract
the appropriate data for these participants from the results.
• Assessment of heterogeneity: we planned to examine the forest plots and use the Chi2 test and I2 test to assess heterogeneity.
• Assessment of reporting bias: we planned to create a funnel plot if there were 10 or more trials in any analysis.
• Data synthesis: we planned to combine data using a random-effects model (unless there was a small number of trials in which
case we would have used a fixed-effect model).
• Subgroup analysis: initially we planned to consider the different types of intervention - restitutive, compensatory, substitutive
and pharmacological - as subgroup analyses, however in reality but the interventions in these categories were so different we
considered that an overall meta-analysis would be unlikely to be informative (even if the data were available), so we considered these
comparisons separately. Other planned subgroup analyses of gender, type of acquired brain injury, side of brain injury, type of eye
movement disorder, deviation of eye movement, and severity of eye movement were also not possible.
• Sensitivity analyses: we planned sensitivity analyses to test the effect of any assumptions regarding missing data, and effects of
publication type and risk of bias.
Additional authors
This review includes the authors Kerry Hanna and Jennifer Evans who were not involved in the protocol authorship.
I N D E X T E R M S
Medical Subject Headings (MeSH)
4-Aminopyridine [∗analogs & derivatives; therapeutic use]; Abducens Nerve Diseases [etiology]; Amines [∗therapeutic use]; Baclofen
[∗therapeutic use]; Botulinum Toxins [adverse effects; ∗therapeutic use]; Brain Injuries [∗complications]; Cyclohexanecarboxylic Acids
[∗therapeutic use];Neuromuscular Agents [adverse effects; ∗therapeutic use];Nystagmus, Pathologic [etiology; therapy];OcularMotility
Disorders [∗drug therapy; etiology]; Randomized Controlled Trials as Topic; Vision, Binocular; Watchful Waiting; gamma-Aminobu-
tyric Acid [∗therapeutic use]
MeSH check words
Humans
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